IL154403A0 - Pharmaceutical formulation of salmeterol and fluticasone propionate - Google Patents
Pharmaceutical formulation of salmeterol and fluticasone propionateInfo
- Publication number
- IL154403A0 IL154403A0 IL15440301A IL15440301A IL154403A0 IL 154403 A0 IL154403 A0 IL 154403A0 IL 15440301 A IL15440301 A IL 15440301A IL 15440301 A IL15440301 A IL 15440301A IL 154403 A0 IL154403 A0 IL 154403A0
- Authority
- IL
- Israel
- Prior art keywords
- salmeterol
- pharmaceutical formulation
- fluticasone propionate
- fluticasone
- propionate
- Prior art date
Links
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229940021597 salmeterol and fluticasone Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Treatment Of Water By Ion Exchange (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22938100P | 2000-08-31 | 2000-08-31 | |
| PCT/GB2001/003928 WO2002017894A2 (en) | 2000-08-31 | 2001-08-31 | Pharmaceutical formulation of salmeterol and fluticasone propionate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL154403A0 true IL154403A0 (en) | 2003-09-17 |
Family
ID=22860986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15440301A IL154403A0 (en) | 2000-08-31 | 2001-08-31 | Pharmaceutical formulation of salmeterol and fluticasone propionate |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20040009963A1 (pl) |
| EP (1) | EP1313484A2 (pl) |
| JP (1) | JP2004507494A (pl) |
| KR (1) | KR20030031997A (pl) |
| CN (1) | CN1449288A (pl) |
| AP (1) | AP2003002753A0 (pl) |
| AR (1) | AR030516A1 (pl) |
| AU (1) | AU2001284236A1 (pl) |
| BG (1) | BG107596A (pl) |
| BR (1) | BR0113555A (pl) |
| CA (1) | CA2420532A1 (pl) |
| EA (1) | EA200300152A1 (pl) |
| EC (1) | ECSP034487A (pl) |
| HU (1) | HUP0303755A2 (pl) |
| IL (1) | IL154403A0 (pl) |
| MA (1) | MA25834A1 (pl) |
| MX (1) | MXPA03001752A (pl) |
| NO (1) | NO20030899L (pl) |
| OA (1) | OA12370A (pl) |
| PE (1) | PE20020387A1 (pl) |
| PL (1) | PL365582A1 (pl) |
| SK (1) | SK2302003A3 (pl) |
| WO (1) | WO2002017894A2 (pl) |
| ZA (1) | ZA200301475B (pl) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0106031D0 (en) * | 2001-03-12 | 2001-05-02 | Glaxo Group Ltd | Use |
| AU2003263717A1 (en) * | 2002-09-25 | 2004-04-19 | Astrazeneca Ab | A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES |
| ES2471139T3 (es) * | 2003-08-06 | 2014-06-25 | Galephar M/F | Combinaciones ventajosas para la inhalaci�n de nacistelina y broncodilatadores |
| TR200907913A2 (tr) * | 2009-10-20 | 2011-05-23 | Bi̇lgi̇ç Mahmut | İnhalason yolu ile alınmak üzere kuru toz formunda farmasötik bileşim |
| US8834931B2 (en) | 2009-12-25 | 2014-09-16 | Mahmut Bilgic | Dry powder formulation containing tiotropium for inhalation |
| TR200909791A2 (tr) * | 2009-12-25 | 2011-07-21 | B�Lg�� Mahmut | Salmeterol ve flutikazon içeren farmasötik bileşim@ |
| TR201000681A2 (tr) * | 2010-01-29 | 2011-08-22 | B�Lg�� Mahmut | İnhalasyon yoluyla alınan kuru toz formülasyonları. |
| US10111957B2 (en) | 2012-07-05 | 2018-10-30 | Arven Ilac Snayi ve Ticaret A.S. | Inhalation compositions comprising glucose anhydrous |
| US10105316B2 (en) | 2012-07-05 | 2018-10-23 | Arven llac Sanayi Ve Ticaret A.S. | Inhalation compositions comprising muscarinic receptor antagonist |
| WO2014007781A2 (en) * | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhalation compositions |
| AU2014261538A1 (en) * | 2013-04-29 | 2015-12-10 | Sanofi Sa | Inhalable pharmaceutical compositions and the inhaler devices containing them |
| MA41378A (fr) * | 2015-01-20 | 2017-11-28 | Teva Branded Pharmaceutical Prod R & D Inc | Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| JP2025528137A (ja) * | 2022-08-08 | 2025-08-26 | ヴェローナ ファーマ ピーエルシー | Ｃｏｐｄ増悪の頻度および／または重症度を減少させるためのエンシフェントリン（ｒｐｌ－５５４） |
| AU2024309346C1 (en) | 2023-06-26 | 2026-03-12 | Verona Pharma Plc | Particulate composition comprising ensifentrine |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant |
| GB9808802D0 (en) * | 1998-04-24 | 1998-06-24 | Glaxo Group Ltd | Pharmaceutical formulations |
| GB9924992D0 (en) * | 1999-10-21 | 1999-12-22 | Glaxo Group Ltd | Pharmaceutical aerosol formulations |
| AU2206801A (en) * | 1999-12-24 | 2001-07-09 | Alan Leslie Cripps | Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate |
-
2001
- 2001-08-29 AR ARP010104122A patent/AR030516A1/es unknown
- 2001-08-29 PE PE2001000867A patent/PE20020387A1/es not_active Application Discontinuation
- 2001-08-31 IL IL15440301A patent/IL154403A0/xx unknown
- 2001-08-31 BR BR0113555-4A patent/BR0113555A/pt not_active Application Discontinuation
- 2001-08-31 CA CA002420532A patent/CA2420532A1/en not_active Abandoned
- 2001-08-31 CN CN01814708A patent/CN1449288A/zh active Pending
- 2001-08-31 HU HU0303755A patent/HUP0303755A2/hu unknown
- 2001-08-31 SK SK230-2003A patent/SK2302003A3/sk unknown
- 2001-08-31 KR KR10-2003-7002890A patent/KR20030031997A/ko not_active Withdrawn
- 2001-08-31 EA EA200300152A patent/EA200300152A1/ru unknown
- 2001-08-31 JP JP2002522868A patent/JP2004507494A/ja active Pending
- 2001-08-31 OA OA1200300054A patent/OA12370A/en unknown
- 2001-08-31 AP APAP/P/2003/002753A patent/AP2003002753A0/en unknown
- 2001-08-31 US US10/363,438 patent/US20040009963A1/en not_active Abandoned
- 2001-08-31 PL PL01365582A patent/PL365582A1/pl not_active Application Discontinuation
- 2001-08-31 MX MXPA03001752A patent/MXPA03001752A/es unknown
- 2001-08-31 WO PCT/GB2001/003928 patent/WO2002017894A2/en not_active Ceased
- 2001-08-31 EP EP01963205A patent/EP1313484A2/en not_active Withdrawn
- 2001-08-31 AU AU2001284236A patent/AU2001284236A1/en not_active Abandoned
-
2003
- 2003-02-20 EC EC2003004487A patent/ECSP034487A/es unknown
- 2003-02-24 ZA ZA200301475A patent/ZA200301475B/en unknown
- 2003-02-26 NO NO20030899A patent/NO20030899L/no not_active Application Discontinuation
- 2003-02-27 BG BG107596A patent/BG107596A/bg unknown
- 2003-02-27 MA MA27058A patent/MA25834A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002017894A3 (en) | 2002-08-08 |
| AR030516A1 (es) | 2003-08-20 |
| ECSP034487A (es) | 2003-03-31 |
| CA2420532A1 (en) | 2002-03-07 |
| MA25834A1 (fr) | 2003-07-01 |
| MXPA03001752A (es) | 2003-06-04 |
| AU2001284236A1 (en) | 2002-03-13 |
| BG107596A (bg) | 2004-01-30 |
| WO2002017894A2 (en) | 2002-03-07 |
| KR20030031997A (ko) | 2003-04-23 |
| PL365582A1 (pl) | 2005-01-10 |
| AP2003002753A0 (en) | 2003-06-30 |
| HUP0303755A2 (hu) | 2004-04-28 |
| JP2004507494A (ja) | 2004-03-11 |
| NO20030899D0 (no) | 2003-02-26 |
| BR0113555A (pt) | 2003-07-22 |
| EP1313484A2 (en) | 2003-05-28 |
| OA12370A (en) | 2004-03-19 |
| SK2302003A3 (en) | 2003-08-05 |
| EA200300152A1 (ru) | 2003-08-28 |
| CN1449288A (zh) | 2003-10-15 |
| ZA200301475B (en) | 2004-05-24 |
| US20040009963A1 (en) | 2004-01-15 |
| NO20030899L (no) | 2003-04-28 |
| PE20020387A1 (es) | 2002-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL349856A1 (en) | Combinations of formoterol and fluticasone propionate for asthma | |
| HUP0301325A3 (en) | Stabilized pharmaceutically effective composition and pharmaceutical composition comprising the same and process for preparation the composition | |
| PL352282A1 (en) | Derivatives of thiazoles and pharmaceutical compositions containing these derivatives | |
| HUP0203451A3 (en) | Pharmaceutical compositions of anti-tubercular drugs and process for their preparation | |
| HUP0301121A3 (en) | Topical pharmaceutical formulations and methods of treatment | |
| AU2002216701A1 (en) | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs | |
| IL154403A0 (en) | Pharmaceutical formulation of salmeterol and fluticasone propionate | |
| AU4672301A (en) | Medical combinations comprising formoterol and fluticasone proprionate | |
| HUP0201872A3 (en) | Steroid compounds and pharmaceutical compositions of the same | |
| HUP0202862A3 (en) | Pharmaceutical composition containing novel combination of loteprednol and antihistamines | |
| HUP0400386A3 (en) | Tablet comprising cetirizine and pseudoephedrine and its use for preparation of pharmaceutical compositions | |
| IL145188A0 (en) | Processes for making pharmaceutical oral ecb formulations and compositions | |
| HUP0300334A3 (en) | Pharmaceutical preparations and their manufacture | |
| AU2002237400A1 (en) | Pharmaceutical formulation comprising r-salmeterol and fluticasone propionate | |
| HUP0303731A3 (en) | Sulfonylguanidines and their use for preparation of pharmaceutical compositions | |
| HUP0300402A3 (en) | Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them | |
| AU4853801A (en) | Medical combination comprising salmeterol and budesonide | |
| AU4853601A (en) | Medical combinations comprising mometasone and salmeterol | |
| AU4854101A (en) | Medical combinations comprising formoterol and mometasone | |
| GB2392164B (en) | Pharmaceutical formulation of fluticasone propionate | |
| PL357020A1 (pl) | Kompozycja | |
| HUP0203383A3 (en) | Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof | |
| IL131266A0 (en) | Peptides and pharmaceutical compositions comprising same | |
| EP1275657A4 (en) | PEPTIDE DERIVATIVES AND MEDICINAL COMPOSITIONS | |
| IL160886A0 (en) | Nicotine containing pharmaceutical formulations and use thereof |